🔒 Lilly's Weight-Loss Pill Approved, Sparking Competition with Novo Nordisk
Eli Lilly's daily weight-loss pill received FDA approval, setting the stage for a competitive battle with Novo Nordisk's Wegovy in the $70 b…
High impact 15 min
Drug profile · INN
semaglutide
OZEMPIC
semaglutide (OZEMPIC) is a glucagon-like peptide 1 receptor agonist. Associated with NovoThirteen. Route of administration: solution. Current US regulatory status: approved.
FDA: approved EMA: approved TGA: approved PMDA: approved NMPA: clinical trials Alimentary tract and metabolism (A10) A10BJ06
US status approved
Patents linked 0
Pipeline programs 56
News articles 6
Congress events 1
Drug details — semaglutide
- US status
- approved
- Class
- Alimentary tract and metabolism (A10)
- Route
- SOLUTION
- Patents
- 0
- Programs
- 56
- Data quality
- 0.84
Quick answer
semaglutide (OZEMPIC) is a glucagon-like peptide 1 receptor agonist. Associated with NovoThirteen. Route of administration: solution. Current US regulatory status: approved.
Key facts
INN semaglutide
Brand OZEMPIC
Mechanism Glucagon-like peptide 1 receptor agonist
Target Glucagon-like peptide 1 receptor
Therapeutic class Alimentary tract and metabolism (A10)
Route SOLUTION
Formulation SOLUTION
ATC code A10BJ06
Originator NovoThirteen
Mechanism of action
Glucagon-like peptide 1 receptor agonist
Primary target: Glucagon-like peptide 1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Weight Loss Medications in 2026: GLP-1 Market Shift
Novo wins UK approval as race to launch weight-loss pill intensifies
Novo Nordisk won UK approval for its oral Wegovy weight-loss pill, making the UK the first European market to allow access. The decision strengthens Novo’s lead in the oral GLP-1 race as Eli Lilly advances orforglipron.
Medicare GLP-1 coverage 2026: Bridge program starts July 1
CMS will launch a temporary Medicare GLP-1 Bridge program on July 1, 2026, creating a new access pathway for eligible beneficiaries. For BD teams, investors, and analysts, the key questions are coverage scope, pricing pressure, and what the demo signals for future reimbursement.
Novo Nordisk supply of Wegovy stabilizes as new capacity comes online
Novo Nordisk says Wegovy supply is stabilizing as FDA-determined shortages of Wegovy and Ozempic are resolved. The company is also investing $4.1 billion to expand manufacturing capacity in Clayton, North Carolina.
Congress & event coverage
- PresentationTHMA Pharmacy Growth
Pipeline programs
Related & competitor drugs
Related research
🔒 
🔒 Ensuring Compatibility for GLP-1-based Drugs
The rise of GLP-1 agonists like Semaglutide demands innovative ready-to-use cartridges to enhance delivery efficiency and reduce costs in ob…
High impact 5 min
Frequently asked questions
What is semaglutide?
semaglutide (OZEMPIC) is a glucagon-like peptide 1 receptor agonist. Associated with NovoThirteen. Route of administration: solution. Current US regulatory status: approved.
What is the brand name for semaglutide?
OZEMPIC is a marketed brand name for semaglutide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of semaglutide?
semaglutide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.